New eye injection shows promise for rare Blindness-Causing gene mutation
NCT ID NCT05902962
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug, VP-001, given as an injection into the eye to see if it is safe for people with a rare genetic eye disease caused by a PRPF31 mutation. Seventeen adults took part. The main goal was to check for side effects, not to measure vision improvement.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRPF31 MUTATIONASSOCIATED RETINAL DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bascom Palmer Eye Institute University of Miami
Miami, Florida, 33136, United States
-
Baylor College of Medicine- Alkek Eye Center
Houston, Texas, 77030, United States
-
Oregon Health and Science University - Casey Eye Institute
Portland, Oregon, 97239, United States
-
Retina Foundation of the Southwest
Dallas, Texas, 75321, United States
-
University of Florida Health
Jacksonville, Florida, 32209, United States
-
University of Michigan Kellogg Eye Center
Ann Arbor, Michigan, 48105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.